Recent Updates
Recently added Catalysts

Pb-MP0712

Phase 1

Large Cell Neuroendocrine Carcinoma | Small molecule | Oncology |Molecular Partners AG|Last Updated: May 22, 2026

Target and mechanism

Molecular targetDelta-like ligand 3
Target classProtein
ModalitySmall molecule

Also known as [212Pb]Pb-MP0712

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment138

FDA Designations

No designations recorded

Clinical trial landscape

Pb-MP0712 · 1 trial · 7 indications

Phase 1 1
NCT07278479Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsLarge Cell Neuroendocrine Carcinoma
RECRUITING138 Analytics
PHASE1RECRUITING
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Large Cell Neuroendocrine Carcinoma
NCT07278479138
Unlock trial analytics

Study Endpoints

Primary Endpoints

To assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279
until 5 years after last dose

Type, frequency and severity of adverse events (AEs), and serious adverse events (SAEs), Adverse events of special interest (AESI) and Dose Limiting Toxicities (DLT) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)

To assess dose modifications of [212Pb]Pb-DOTAM-MAM279
until 5 years after last dose

Frequency and duration of dose changes

To estimate the maximum tolerated dose (MTD) and/or to define the recommended phase 2 dose (RP2D) for SCLC/LCNEC of the lung and epNECs
Phase 1, from start of treatment to end of first cycle (day 1 - 28)

Incidence of dose limiting toxicities

To evaluate the preliminary anti-tumor activity of [212Pb]Pb-DOTAM-MAM279 in the dose expansion part
Phase 2a only; 12 months

Objective Response Rate (ORR) in the expansion phase ORR is defined as the percentage of patients with partial response (PR) or complete response (CR) as per RECIST v1.1

Secondary Endpoints

To assess maximum concentration (Cmax) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
To assess the area under the curve (AUC) from time 0 to the time of the last quantifiable concentration of [203Pb]Pb-DOTAM-MAM279
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
To assess half-live(s) (t½) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
[203Pb]Pb-DOTAM-MAM279/[212Pb]Pb-DOTAM-MAM279EXPERIMENTALPatients will receive \[203Pb\]Pb-DOTAM-MAM279 for Imaging/Dosimetry followed by \[212Pb\]Pb-DOTAM-MAM279 for treatment

Interventions

NameTypeDescription
[212Pb]Pb-MP0712DRUGRadioligand Therapy
[203Pb]Pb-MP0712OTHERRadioligand Imaging Agent
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites5

Key Inclusion Criteria: * Age ≥ 18 years old * Histologically or cytologically confirmed: I. advanced extensive or limited SCLC or LC NECs of the lung * SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based t...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Pb-MP0712

What is Pb-MP0712 used for?

Pb-MP0712, also known as [212Pb]Pb-MP0712, is an investigational small molecule being developed for the treatment of Large Cell Neuroendocrine Carcinoma and other DLL3-expressing solid tumors, including Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, and Gastroenteropancreatic NEC. It is currently in Phase 1 clinical development.

What does Pb-MP0712 target?

Pb-MP0712 targets Delta-like ligand 3 (DLL3), a protein expressed on the surface of certain tumor cells. By binding to DLL3, the drug is designed to deliver a radioactive payload, lead-212, directly to cancer cells. This targeted approach aims to minimize damage to healthy tissues while attacking DLL3-positive tumors.

Who makes Pb-MP0712?

Pb-MP0712 is being developed by Molecular Partners AG, a biopharmaceutical company traded on the Nasdaq under the ticker symbol MOLN. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with DLL3-expressing solid tumors.

What phase is Pb-MP0712 in?

Pb-MP0712 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities such as the FDA. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and preliminary activity in patients with certain types of cancer.

What clinical trials is Pb-MP0712 in?

Pb-MP0712 is being studied in a Phase 1 clinical trial registered as NCT07278479. This open-label, uncontrolled study is recruiting approximately 138 participants in the United States. The trial is evaluating the drug in patients with Small Cell Lung Cancer, Large Cell Neuroendocrine Carcinoma, and other DLL3-expressing solid tumors.

Is Pb-MP0712 the same as [212Pb]Pb-MP0712?

Yes, Pb-MP0712 and [212Pb]Pb-MP0712 refer to the same investigational drug. The name [212Pb]Pb-MP0712 specifies the lead-212 isotope attached to the molecule, while Pb-MP0712 is the shorter, commonly used name. Both names appear in clinical trial documentation for the same drug candidate.